Actrapid: Uses, Dosage & Side Effects
A fast-acting soluble human insulin for the treatment of diabetes mellitus, lowering blood glucose by replacing or supplementing the body's own insulin
Actrapid is a fast-acting soluble insulin containing human insulin produced by recombinant DNA technology using Saccharomyces cerevisiae. It is used for the treatment of diabetes mellitus in adults, adolescents, and children who require insulin to control their blood glucose levels. Actrapid is typically injected subcutaneously approximately 30 minutes before a meal, has an onset of action within 30 minutes, peaks at 1.5–3.5 hours, and has a duration of approximately 7–8 hours. It is included on the WHO Model List of Essential Medicines and has been a cornerstone of diabetes therapy for decades. Actrapid can also be administered intravenously or intramuscularly under medical supervision in clinical settings such as diabetic ketoacidosis management.
Quick Facts: Actrapid
Key Takeaways
- Actrapid is a fast-acting soluble human insulin that begins working within 30 minutes of subcutaneous injection, peaks at 1.5–3.5 hours, and lasts approximately 7–8 hours, making it suitable for mealtime blood glucose control.
- It is used for type 1 diabetes, type 2 diabetes, gestational diabetes, and diabetic emergencies (ketoacidosis, hyperglycemic crises) when administered intravenously in hospital settings.
- Hypoglycemia (low blood sugar) is the most common and potentially serious side effect; patients must learn to recognize warning signs and always carry a source of fast-acting sugar.
- Actrapid should be injected subcutaneously about 30 minutes before meals, and injection sites should be rotated within the same anatomical region to prevent lipodystrophy (fatty lumps under the skin).
- Never change your insulin type, brand, or dose without medical supervision, as even small changes can significantly affect blood glucose control and lead to dangerous highs or lows.
What Is Actrapid and What Is It Used For?
Actrapid contains the active substance insulin human, which is identical to the insulin naturally produced by the beta cells of the pancreas. It is manufactured using recombinant DNA technology in Saccharomyces cerevisiae (baker's yeast), ensuring a highly purified product that is bioidentical to endogenous human insulin. Unlike insulin analogues that have modified amino acid sequences for altered pharmacokinetics, Actrapid contains unmodified human insulin in a soluble (neutral) formulation, giving it a well-characterized and predictable absorption profile that has been validated in clinical practice over several decades.
Insulin is a peptide hormone essential for life. It plays a central role in glucose metabolism by facilitating the uptake of glucose from the bloodstream into cells, particularly in skeletal muscle and adipose tissue. It also promotes glycogen synthesis in the liver, stimulates lipogenesis, and enhances protein synthesis while simultaneously inhibiting hepatic glucose production (gluconeogenesis), glycogen breakdown (glycogenolysis), lipolysis, and proteolysis. In people with diabetes, the body either does not produce sufficient insulin (type 1 diabetes) or cannot use it effectively (type 2 diabetes), leading to chronically elevated blood glucose levels that, if left untreated, cause devastating complications affecting the eyes, kidneys, nerves, heart, and blood vessels.
Actrapid is classified as a short-acting (regular) insulin. After subcutaneous injection, it begins to lower blood glucose within approximately 30 minutes, reaches its maximum effect between 1.5 and 3.5 hours, and continues to exert a glucose-lowering effect for approximately 7 to 8 hours. This pharmacokinetic profile makes Actrapid particularly suitable for controlling postprandial (after-meal) blood glucose spikes when injected about half an hour before eating. When administered intravenously in a hospital setting, the onset of action is almost immediate, making it invaluable for managing diabetic emergencies such as diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS).
Actrapid is approved and used worldwide for the following indications:
- Type 1 diabetes mellitus: As part of a basal-bolus insulin regimen, Actrapid serves as the mealtime (bolus) insulin, typically combined with an intermediate-acting or long-acting insulin (such as Insulatard/NPH insulin or a basal insulin analogue) to provide 24-hour blood glucose coverage. All patients with type 1 diabetes require lifelong insulin replacement therapy.
- Type 2 diabetes mellitus: When oral antidiabetic medications and lifestyle modifications are insufficient to achieve adequate glycemic control, insulin therapy may be initiated. Actrapid can be used as the mealtime component of an insulin regimen, or in combination with oral medications and basal insulin, to achieve target blood glucose levels.
- Gestational diabetes: Actrapid is a well-established choice for managing blood glucose during pregnancy when dietary measures alone are insufficient. Human insulin has the longest safety track record in pregnancy of any insulin formulation.
- Diabetic emergencies: Actrapid can be administered intravenously for the management of diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar state (HHS), and perioperative blood glucose control. Intravenous administration provides precise, rapid glucose lowering with easy dose titration.
Actrapid is included on the WHO Model List of Essential Medicines, underscoring its fundamental importance in global healthcare. It remains one of the most widely used insulin formulations worldwide, particularly in low- and middle-income countries where it represents a cost-effective, life-saving treatment for millions of people with diabetes.
Actrapid contains unmodified human insulin, as opposed to insulin analogues (such as insulin lispro, insulin aspart, or insulin glulisine) that have been genetically modified for faster or more prolonged action. While rapid-acting insulin analogues have a somewhat faster onset and shorter duration, human soluble insulin like Actrapid remains a highly effective and more affordable option. International guidelines including ADA and WHO consider human insulin and analogues equally appropriate for most patients.
What Should You Know Before Taking Actrapid?
Contraindications
There are specific situations in which Actrapid must not be used. Understanding these contraindications is essential for safe insulin therapy and preventing potentially life-threatening hypoglycemia.
- Hypersensitivity: Do not use Actrapid if you are allergic to human insulin or any of the other ingredients (metacresol, zinc chloride, glycerol, hydrochloric acid, sodium hydroxide, or water for injection). True insulin allergy is rare but can cause local or systemic reactions including anaphylaxis.
- Hypoglycemia: Never inject Actrapid when your blood sugar is already low or dropping. Insulin must not be administered during active hypoglycemic episodes, as it will further reduce blood glucose to dangerous levels.
- Insulin pump use: Actrapid must not be used in insulin infusion pumps, as it is not designed for this purpose. Only specifically formulated rapid-acting insulin analogues should be used in pumps.
Warnings and Precautions
Hypoglycemia (low blood sugar) is the most common serious adverse effect of insulin therapy and can be life-threatening. Symptoms include sweating, trembling, hunger, confusion, dizziness, palpitations, and blurred vision. Severe hypoglycemia can cause unconsciousness, seizures, brain damage, and death. Always carry a source of fast-acting sugar (glucose tablets, juice, or sugar cubes). Make sure family members and close contacts know how to administer glucagon in an emergency.
Before and during treatment with Actrapid, inform your doctor about all relevant conditions and circumstances:
- Kidney disease: Reduced kidney function can slow insulin clearance from the body, potentially increasing the risk of hypoglycemia. Your insulin dose may need to be reduced.
- Liver disease: Impaired liver function affects glucose production and insulin metabolism, requiring careful dose adjustment and more frequent blood glucose monitoring.
- Adrenal, pituitary, or thyroid disorders: These endocrine conditions affect glucose metabolism and may alter insulin requirements. Your doctor will assess how these conditions interact with your insulin needs.
- Switching insulin: Never change from one insulin product to another without medical supervision. Changes in manufacturer, type, method of manufacture, strength, brand, species (human vs. analogue), or formulation may require a dose change. Monitor blood glucose closely during any transition period.
- Exercise and diet: Physical activity increases glucose uptake by muscles independently of insulin, which can lower blood glucose. Changes in diet, meal timing, or exercise patterns may require insulin dose adjustments. Always consult your diabetes care team when making significant lifestyle changes.
- Illness and stress: Infections, fever, surgery, emotional stress, and other illnesses can cause blood glucose levels to rise significantly. You may need to increase your insulin dose during these periods. Never stop insulin completely, even if you cannot eat, as this can lead to diabetic ketoacidosis.
- Injection technique: Rotate injection sites within the same anatomical region (abdomen, thigh, upper arm, or buttock) to prevent lipodystrophy, which can impair insulin absorption. Absorption rate varies between body regions: the abdomen provides the fastest and most consistent absorption.
- Alcohol: Alcohol can both increase and decrease blood glucose levels. It can impair the liver's ability to produce glucose, increasing the risk of delayed hypoglycemia, particularly overnight. Alcohol can also mask the warning symptoms of hypoglycemia. Drink only in moderation and always with food.
- Driving and machinery: Hypoglycemia and hyperglycemia can impair concentration and reaction time. Check your blood glucose before driving and at regular intervals during long journeys. Carry glucose in your vehicle and stop driving immediately if you feel unwell.
- Thiazolidinedione combination: Using insulin together with pioglitazone (a thiazolidinedione) may increase the risk of heart failure due to fluid retention, especially in patients with pre-existing cardiac risk factors. Tell your doctor immediately if you experience swelling, weight gain, or shortness of breath.
Pregnancy and Breastfeeding
Actrapid can be used during pregnancy. Maintaining good blood glucose control throughout pregnancy is essential for both the mother's and baby's health. Poorly controlled diabetes during pregnancy increases the risk of congenital malformations, macrosomia, birth injury, pre-eclampsia, and neonatal hypoglycemia. Human insulin does not cross the placenta and has the longest established safety record of any insulin formulation in pregnancy.
Insulin requirements typically decrease during the first trimester, increase during the second and third trimesters, and fall sharply after delivery. Close monitoring and frequent dose adjustments are necessary throughout pregnancy and the postpartum period. Your diabetes team will work with you to optimize blood glucose control at every stage.
Actrapid can also be used during breastfeeding. Insulin is broken down in the infant's gastrointestinal tract and is not absorbed into the bloodstream, so it poses no risk to the breastfed child. However, your insulin dose may need adjustment during breastfeeding due to changes in energy expenditure and hormonal status.
How Does Actrapid Interact with Other Drugs?
Numerous medications can interact with Actrapid by either increasing or decreasing its blood glucose-lowering effect. Some drugs may mask the symptoms of hypoglycemia, making it harder to recognize dangerously low blood sugar. It is essential to inform your doctor, pharmacist, or diabetes nurse about all medicines, supplements, and herbal products you are taking, including those obtained without a prescription.
Drugs That May Increase the Hypoglycemic Effect (Risk of Low Blood Sugar)
| Drug / Drug Class | Mechanism | Clinical Significance |
|---|---|---|
| Oral antidiabetic agents (sulfonylureas, metformin, SGLT2 inhibitors) | Additive glucose-lowering effect | Monitor closely; dose reduction of insulin or oral agent may be needed |
| ACE inhibitors (enalapril, ramipril, lisinopril) | Increase insulin sensitivity | Monitor blood glucose more frequently when starting or stopping |
| MAO inhibitors | Enhance insulin secretion and sensitivity | Significant hypoglycemia risk; close monitoring required |
| Salicylates (high-dose aspirin) | Increase peripheral glucose utilization | Monitor at high anti-inflammatory doses |
| Alcohol | Inhibits hepatic gluconeogenesis | Risk of delayed severe hypoglycemia, especially overnight |
Drugs That May Decrease the Hypoglycemic Effect (Risk of High Blood Sugar)
| Drug / Drug Class | Mechanism | Clinical Significance |
|---|---|---|
| Corticosteroids (prednisolone, dexamethasone) | Stimulate gluconeogenesis, decrease insulin sensitivity | Significant hyperglycemia; insulin dose increase often needed |
| Thiazide diuretics (hydrochlorothiazide) | Impair insulin secretion, increase insulin resistance | Monitor blood glucose; consider dose adjustment |
| Oral contraceptives | Estrogen and progestogen increase insulin resistance | Monitor when starting or stopping; adjust insulin as needed |
| Thyroid hormones (levothyroxine) | Increase hepatic glucose output and metabolic rate | Insulin requirements may increase with thyroid replacement |
| Sympathomimetics (salbutamol, terbutaline, adrenaline) | Stimulate glycogenolysis and gluconeogenesis | Monitor glucose during use; temporary dose increase may be needed |
| Growth hormone (somatotropin) | Promotes insulin resistance | Insulin dose increase usually required |
Drugs That May Mask Hypoglycemia Symptoms
Beta-blockers (such as propranolol, atenolol, metoprolol, and bisoprolol) can mask the typical adrenergic warning signs of hypoglycemia, including trembling, palpitations, and anxiety. If you take a beta-blocker, you may not notice the early symptoms of low blood sugar, making severe hypoglycemia more likely. Your doctor may recommend more frequent blood glucose monitoring. Non-selective beta-blockers (e.g., propranolol) have a greater masking effect than cardioselective agents (e.g., bisoprolol).
Clonidine and other centrally acting antihypertensives may similarly reduce awareness of hypoglycemic symptoms. Octreotide and lanreotide (somatostatin analogues) may either increase or decrease insulin requirements and should be used with careful glucose monitoring.
What Is the Correct Dosage of Actrapid?
The dose of Actrapid is always individualized. Your doctor will determine the correct dose based on your blood glucose levels, eating patterns, exercise habits, and overall metabolic needs. There is no single correct dose – the right amount is the dose that achieves your target blood glucose levels without causing unacceptable hypoglycemia. Regular self-monitoring of blood glucose is essential to guide dose adjustments.
Adults
Type 1 Diabetes – Basal-Bolus Regimen
Total daily insulin: Typically 0.5–1.0 IU/kg/day
Actrapid (mealtime): Usually 50–60% of total daily dose, divided across meals
Timing: Inject subcutaneously approximately 30 minutes before each meal
Basal insulin: The remaining 40–50% is covered by intermediate-acting (NPH/Insulatard) or long-acting insulin
Type 2 Diabetes – Supplemental Insulin
Starting dose: Often initiated at 4–6 IU before the largest meal, then titrated
Timing: Inject subcutaneously approximately 30 minutes before meals
Combination: May be used alongside oral antidiabetic agents and/or basal insulin
Dose is titrated based on pre-meal and post-meal blood glucose targets set by your doctor.
Intravenous Administration (Hospital Setting Only)
Indication: Diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar state (HHS), perioperative management
Concentration: 0.05–1.0 IU/mL in 0.9% sodium chloride or 5% glucose infusion
Rate: Determined by the treating physician based on blood glucose monitoring (typically every 1–2 hours)
Intravenous insulin provides immediate onset and allows for precise dose titration. It must only be administered under medical supervision with continuous blood glucose and electrolyte monitoring.
Children and Adolescents
Actrapid can be used in children and adolescents with diabetes mellitus. The dosing principles are the same as for adults, but insulin requirements vary considerably depending on the child's age, growth stage, pubertal status, and activity level. During puberty, insulin requirements often increase significantly (up to 1.5 IU/kg/day or more) due to growth hormone and sex hormone-related insulin resistance. After puberty, requirements typically decrease.
Children under 6 years may be more sensitive to insulin, and smaller, more precise doses may be required. A pediatric endocrinologist should oversee insulin therapy in young children.
Elderly
There is no specific age-related dose adjustment for Actrapid. However, elderly patients may be at increased risk of hypoglycemia due to reduced kidney function, decreased counter-regulatory hormone responses, irregular eating patterns, or cognitive impairment affecting self-management. Less stringent blood glucose targets (HbA1c 7.5–8.5% / 58–69 mmol/mol) may be appropriate for older adults, especially those with multiple comorbidities or limited life expectancy, as recommended by ADA guidelines.
Missed Dose
If you forget to inject Actrapid before a meal, do not take a double dose to compensate. Check your blood glucose. If it is elevated, you may inject a corrective dose as advised by your doctor. If the next meal is approaching, take your usual pre-meal dose at the usual time. Missing a dose can lead to hyperglycemia, which, if prolonged, may cause diabetic ketoacidosis in type 1 diabetes. Contact your diabetes care team if you are unsure what to do.
Overdose
An overdose of Actrapid causes hypoglycemia, which can be life-threatening. Mild hypoglycemia: Immediately eat 15–20 grams of fast-acting carbohydrates (glucose tablets, fruit juice, or sugar). Recheck blood glucose after 15 minutes and repeat if needed. Severe hypoglycemia (unconsciousness, seizures, inability to swallow): Another person should administer glucagon injection (if available and trained) and call emergency services immediately. Do NOT attempt to give food or drink to an unconscious person. Intravenous glucose will be administered by medical professionals.
What Are the Side Effects of Actrapid?
Like all medicines, Actrapid can cause side effects, although not everyone experiences them. The frequency and severity of side effects depend on factors such as dose, injection technique, diet, exercise, and individual sensitivity. Hypoglycemia is by far the most common adverse effect and the primary safety concern with any insulin therapy. Your healthcare team will work with you to minimize the risk of side effects through appropriate dosing, education, and monitoring.
Very Common
May affect more than 1 in 10 people
- Hypoglycemia (low blood sugar) – symptoms include sweating, trembling, hunger, confusion, dizziness, palpitations, blurred vision, weakness, headache, and difficulty concentrating. Severe hypoglycemia can cause unconsciousness, seizures, and may be life-threatening
Uncommon
May affect up to 1 in 100 people
- Visual disturbances – temporary blurring of vision, particularly when starting insulin therapy or making significant dose changes, due to changes in lens refraction as blood glucose levels normalize. This usually resolves within a few weeks
- Injection site reactions – redness, swelling, itching, warmth, or bruising at the injection site. These are usually mild and transient
- Lipodystrophy – thickening of fatty tissue (lipohypertrophy) or loss of fatty tissue (lipoatrophy) at the injection site, caused by repeated injection into the same area. Prevention involves systematic rotation of injection sites
- Peripheral edema – swelling of the ankles and feet, particularly when insulin therapy is initiated or intensified. This is caused by temporary sodium and water retention and usually resolves spontaneously
Rare
May affect up to 1 in 1,000 people
- Allergic reactions (local) – generalized skin reactions including urticaria (hives), rash, and itching beyond the injection site
- Diabetic retinopathy worsening – rapid improvement in blood glucose control in patients with pre-existing diabetic retinopathy may temporarily worsen retinal changes. This is a recognized phenomenon and does not mean insulin should be stopped; long-term glycemic control is protective
- Peripheral neuropathy – painful peripheral neuropathy (treatment-induced neuropathy) may rarely occur with rapid improvement in blood glucose control. This is typically transient and resolves as the body adjusts
Not Known
Frequency cannot be estimated from available data
- Severe allergic reactions (anaphylaxis) – extremely rare but potentially life-threatening generalized allergic reactions including difficulty breathing, rapid heartbeat, drop in blood pressure, and generalized swelling. Seek emergency medical attention immediately
- Hypokalemia – insulin promotes cellular uptake of potassium, which can lower blood potassium levels. This is particularly relevant during intravenous insulin therapy and in patients taking potassium-lowering medications. Electrolytes should be monitored
Some people, particularly those with long-standing diabetes, frequent hypoglycemic episodes, or those taking beta-blockers, may develop reduced awareness of hypoglycemia symptoms (hypoglycemia unawareness). This means the normal warning signs (sweating, trembling, hunger) are diminished or absent, and the first sign may be confusion or loss of consciousness. If you suspect you have reduced hypoglycemia awareness, discuss this with your doctor immediately. More frequent blood glucose monitoring and slightly higher glucose targets may be recommended.
If you experience any side effects, including those not listed here, tell your doctor, nurse, or pharmacist. You can also report suspected side effects to your national pharmacovigilance authority (e.g., the EMA in Europe, the FDA MedWatch program in the United States, or the MHRA Yellow Card Scheme in the United Kingdom).
How Should You Store Actrapid?
Proper storage of insulin is essential to maintain its effectiveness. Insulin that has been exposed to extreme temperatures, frozen, or stored beyond its recommended period may lose potency without any visible change in appearance, leading to poor blood glucose control.
- Before opening: Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Keep away from the freezing compartment. Do not freeze. If Actrapid has been frozen, it must not be used.
- During use: Actrapid that is currently in use can be stored at room temperature (below 25°C / 77°F) for up to 6 weeks. Do not refrigerate the vial you are currently using, as cold insulin injections can be uncomfortable and may affect absorption.
- Light protection: Keep the vial in the outer carton when not in use to protect from light.
- Inspection before use: Actrapid should always be clear and colorless. Do not use if it appears cloudy, discolored, or contains particles. Cloudy insulin is a sign of degradation or contamination.
- Travel: When traveling, carry insulin in a cool bag or insulated case. Do not store insulin in a car glove compartment, direct sunlight, or checked luggage (cargo holds may reach freezing temperatures). Carry a letter from your doctor confirming your need for insulin and injection supplies.
- Expiry date: Do not use after the expiry date printed on the label. The expiry date refers to the last day of that month.
Keep Actrapid out of the sight and reach of children. Do not dispose of medicines via wastewater or household waste. Ask your pharmacist about proper disposal of medicines you no longer need.
What Does Actrapid Contain?
Active Substance
The active substance is insulin human (rDNA), produced by recombinant DNA technology in Saccharomyces cerevisiae. Each milliliter contains 40 International Units (IU) of soluble insulin human. The insulin molecule is identical to naturally occurring human insulin, consisting of two polypeptide chains (A chain: 21 amino acids; B chain: 30 amino acids) connected by two disulfide bridges.
Excipients (Inactive Ingredients)
- Zinc chloride: Stabilizes the insulin hexamer structure, ensuring product stability and consistent dissolution
- Glycerol (glycerin): Acts as a tonicity agent to make the solution isotonic with body fluids, reducing pain at the injection site
- Metacresol: Serves as an antimicrobial preservative, allowing the vial to be used for multiple injections over the in-use period
- Hydrochloric acid and/or sodium hydroxide: Used for pH adjustment to approximately 7.4 (physiological pH)
- Water for injection: The solvent base
Appearance and Packaging
Actrapid is a clear, colorless, aqueous solution supplied in 10 mL glass vials. Each vial contains 400 IU of insulin human (40 IU/mL × 10 mL). The vials are sealed with rubber stoppers and aluminum caps and are supplied in cardboard cartons. The solution should always be inspected before use – do not use if it appears anything other than clear, colorless, and free of particles.
Actrapid 40 IU/mL should not be confused with insulin products at 100 IU/mL concentration (such as Actrapid Penfill, which contains 100 IU/mL for use with insulin pen devices). Always verify the concentration on the vial label and use the appropriate syringe calibrated for the correct concentration to avoid dosing errors. Using a U-100 syringe with U-40 insulin (or vice versa) will result in an incorrect dose.
Frequently Asked Questions About Actrapid
Actrapid contains unmodified human soluble insulin, while rapid-acting insulin analogues (such as insulin lispro/Humalog, insulin aspart/NovoRapid, and insulin glulisine/Apidra) are genetically engineered versions of insulin with altered amino acid sequences. The key practical difference is timing: Actrapid should be injected 30 minutes before a meal, while rapid-acting analogues can be injected 0–15 minutes before eating. Analogues also have a shorter duration of action (3–5 hours vs. 7–8 hours). In terms of overall blood glucose control (HbA1c), large clinical studies and meta-analyses have shown comparable efficacy between human insulin and analogues. The WHO and many international guidelines consider both equally appropriate for most patients, though analogues may offer modestly lower rates of hypoglycemia.
Yes, Actrapid can be mixed with intermediate-acting and long-acting Novo Nordisk insulin preparations (such as Insulatard/NPH insulin) in the same syringe. When mixing, always draw the clear Actrapid into the syringe first, then draw the cloudy longer-acting insulin. Use the mixture immediately after preparation. Do not mix Actrapid with insulin analogues, animal-source insulins, insulins from other manufacturers, or any other medications in the same syringe. Never mix insulin into intravenous infusion fluids unless directed by a healthcare professional in a clinical setting.
If you inject more Actrapid than prescribed, your blood glucose may drop to dangerously low levels (hypoglycemia). For mild hypoglycemia (you are conscious and able to swallow): immediately consume 15–20 grams of fast-acting carbohydrates such as glucose tablets, fruit juice, or regular soft drink. Wait 15 minutes, recheck your blood glucose, and repeat the treatment if levels are still low. Follow up with a complex carbohydrate snack. For severe hypoglycemia (unconsciousness or inability to swallow): a trained companion should inject glucagon, and emergency medical services should be called immediately. Do not attempt to give food or drink to an unconscious person. Always inform your doctor about significant hypoglycemic episodes so your insulin regimen can be reviewed.
Yes, Actrapid can be used during pregnancy and is considered safe. Human insulin does not cross the placenta, and Actrapid has the longest established safety record of any insulin formulation in pregnancy. Good blood glucose control during pregnancy is essential to prevent complications such as congenital malformations, macrosomia (excessively large baby), birth injuries, pre-eclampsia, and neonatal hypoglycemia. Insulin requirements change significantly during pregnancy: they typically decrease in the first trimester, increase during the second and third trimesters, and drop sharply after delivery. Close monitoring by your diabetes and obstetric team is essential throughout pregnancy.
Injection site rotation is crucial to prevent lipodystrophy (changes in fatty tissue) which can impair insulin absorption and lead to erratic blood glucose levels. The recommended injection areas are the abdomen (avoiding 5 cm around the navel), the front of the thighs, the upper outer area of the buttocks, and the outer upper arm. Move the injection point at least 1–2 cm from the previous injection within the same anatomical area. Keep the same body region for the same time of day (e.g., abdomen for morning injections, thighs for evening) to maintain consistent absorption. The abdomen provides the fastest and most consistent absorption for Actrapid. Inspect your injection sites regularly for lumps or indentations and avoid injecting into these areas.
The 30-minute pre-meal injection timing is important because Actrapid needs time to be absorbed from the subcutaneous tissue into the bloodstream. Unlike rapid-acting insulin analogues that begin working in 10–15 minutes, Actrapid takes approximately 30 minutes to start lowering blood glucose. By injecting 30 minutes before eating, the insulin activity coincides with the rise in blood glucose from the digested meal, providing optimal postprandial (after-meal) glucose control. Injecting at the time of the meal or after eating may result in a mismatch between the meal-related glucose spike and the insulin action, leading to higher post-meal blood glucose levels followed by a risk of later hypoglycemia as the insulin continues to act.
References
This article is based on the following peer-reviewed sources and internationally recognized medical guidelines:
- European Medicines Agency (EMA). Actrapid – Summary of Product Characteristics (SmPC). European Medicines Agency, 2025. Available at: www.ema.europa.eu
- American Diabetes Association (ADA). Standards of Care in Diabetes – 2025. Diabetes Care. 2025;48(Suppl 1):S1–S312. doi:10.2337/dc25-SINT
- Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–2786.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: World Health Organization; 2023.
- International Diabetes Federation (IDF). IDF Diabetes Atlas, 10th Edition. Brussels: IDF; 2021. Available at: www.diabetesatlas.org
- Holt RIG, DeVries JH, Hess-Fischl A, et al. The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2021;44(11):2589–2625.
- National Institute for Health and Care Excellence (NICE). Type 1 Diabetes in Adults: Diagnosis and Management (NG17). London: NICE; 2022 (updated).
- Fullerton B, Jeitler K, Seitz M, et al. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2014;(2):CD009122.
About Our Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians and clinical pharmacologists with expertise in endocrinology, diabetes management, and pharmacotherapy. Our team follows international clinical guidelines from the WHO, ADA, EASD, EMA, and NICE, and all content adheres to the GRADE evidence framework to ensure the highest level of medical accuracy.
Evidence Standards
- Evidence Level 1A (systematic reviews and RCTs)
- GRADE evidence framework
- Peer-reviewed sources only
- No commercial funding or sponsorship
Review Process
- Written by medical content specialists
- Reviewed by board-certified physicians
- Fact-checked against primary sources
- Updated regularly as new evidence emerges
Last medical review: | Next scheduled review:
Learn more about our medical team | Read our editorial standards